Completed PHASE1 INTERVENTIONAL 2-arm NCT00559026

Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients (DTIC-melvacc)

Phase I/II Clinical Trial for the Evaluation of the Interaction Between Chemotherapy and Immunotherapy in Melanoma Patients

Sponsor: Istituto Superiore di Sanità

Conditions Melanoma

Interventions Melan-A Melan-A plus Dacarbazine

Updated 4 times since 2017 Last updated: Nov 15, 2007 Started: Sep 30, 2004 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Melanoma and is currently completed. Istituto Superiore di Sanità leads this study, which shows 4 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituto Superiore di Sanità
Regina Elena Cancer Institute
University of Rome Tor Vergata

Data source: Istituto Superiore di Sanità

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy